Our newest investor presentation features:

1. Update on progress of "East to West" cellular immunotherapy strategy including prioritisation of two solid cancer CAR-T assets and potential to access platform technology for future products (slide 9)

2. Additional pre-clinical and clinical data highlighting why we are so excited about the two priority CAR-T assets (slides 10 and 11)

3. Continued activity and discussions to out-license AD-214 for fibrosis (slide 13) and WD-34 for malaria (slide 17)